Both your recent posts right on. That's why much volatility in bio's. Potential, rumors, FDA, cash position, dilution all matter. Revenue and sales occur after PPS has fluctuated. Look at DNDN, 2-3 to 40. A few bad quarters and down to 7-8. That is one reason why I do not exercise options. Too much risk after the runup!!
Market Data 
Markets 
AI
